Abstracts tagged "Lupus"

Abstract Number: 385 • 2015 ACR/ARHP Annual Meeting
Urinary Cell-Free Microrna’s As Biomarkers of Lupus Nephritis in Children
Khalid Abulaban¹, Ndate Fall², Jun Ying³, Kasha Wiley⁴, Ravi Nunna³, Prasad Devarajan⁵, Alexei A. Grom⁴, Michael Bennett⁶, Stacy P. Ardoin⁷ and Hermine I. Brunner⁸, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Division of Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH, ³University of Cincinnati, Cincinnati, OH, ⁴Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Dept of Nephrology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ⁶Division of Nephrology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ⁷Pediatric & Adult Rheumatology, Ohio State University, Columbus, OH, ⁸Pediatric Rheumatology Collaborative Study Group, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: MicroRNAs (miRNAs) are single-stranded RNAs involved in the regulation of host genome expression at the post-transcriptional level. The objective of this study was to…
Abstract Number: 777 • 2015 ACR/ARHP Annual Meeting
SLE-KeyTM Rule-out Test to Assess Lupus in Anti-Nuclear Antibody Positive Subjects Using the Immunarray iCHIP®
D. Scott Batty¹, I.R. Cohen², Chaim Putterman³, Nicole Jordan⁴, Keren Jakobi⁵, Rachel Sorek⁵, Yakov Blumenstein⁵, Pennina Safer⁵ and David Pisetsky⁶, ¹ImmunArray Inc., Richmond, VA, ²Weizmann Institute of Science, Rehovot, Israel, ³Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁴Montefiore Medical Center, New York, NY, ⁵ImmunArray LTD, Rehovot, Israel, ⁶Duke University Medical Center and Durham VAMC, Durham, NC
Background/Purpose: SLE is associated with a broad spectrum of autoantibodies, but currently there is no single serologic test to diagnose SLE definitively. Diagnosis is thus…
Abstract Number: 1236 • 2015 ACR/ARHP Annual Meeting
Google-Driven Search for Autoimmune Big Data Links Air Pollution and Younger Age at Diagnosis of Systemic Lupus Erythematosus: Geoepidemiological Analysis of 171,000 Adult Patients
Manuel Ramos-Casals¹, Pilar Brito-Zerón¹, Belchin Kostov², Soledad Retamozo¹, Antoni Sisó-Almirall², Xavier Bosh³, David Buss⁴, Courtney Grant⁵, Daphne Superville⁶, Antoni Trilla⁷, Yehuda Shoenfeld⁸, John H. Stone⁹ and Munther Khamashta¹⁰, ¹Department of Autoimmune Diseases, CELLEX-IDIBAPS, Hospital Clínic, Barcelona, Barcelona, Spain, ²Primary Care Research Group, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Primary Care Centre Les Corts, CAPSBE, Barcelona, Spain, ³Department of Internal Medicine, ICMiD, Hospital Clínic, Barcelona, Spain, ⁴Department of Autoimmune Diseases, ICMiD, Hospital Clínic, Department of Autoimmune Diseases, CELLEX-IDIBAPS, Hospital Clínic, Barcelona, Barcelona, Spain, ⁵University of Glasgow, Glasgow, United Kingdom, ⁶Massachusetts Institute of Technology (MIT), Cambridge, MA, ⁷Preventive Medicine and Epidemiology Unit, Hospital Clínic-Universitat de Barcelona-Barcelona Centre for International Health Research, Barcelona, Spain, ⁸Zabludowicz Center for Autoimmune Diseases, Chaim Sheba Medical Center, Tel Hashomer, Israel Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel, ⁹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ¹⁰Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom
Background/Purpose: Systemic autoimmune diseases (SAD) are characterized by a wide spectrum of demographic patterns with respect to the age at diagnosis, gender distribution and ethnic differences.…
Abstract Number: 1871 • 2015 ACR/ARHP Annual Meeting
Familial Aggregation of Rheumatoid Arthritis, Sjögren’s Syndrome, and Systemic Sclerosis Were Detected in Systemic Lupus Erythematous Families
Rufei Lu¹, Hua Chen¹, Krista Bean¹, Teresa Aberle¹, Joel Guthridge¹ and Judith James^1,2, ¹Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Medicine & Pathology, Univ. of Oklahoma, Okla, OK
Background/Purpose: Many systemic autoimmune diseases share heritable and non-heritable risks, as well as some clinical manifestations. A recent meta-analysis based upon genome-wide genetic studies contrasting…
Abstract Number: 3082 • 2015 ACR/ARHP Annual Meeting
Nanogel Based Delivery of an Inhibitor of Calcium/ Calmodulin- Dependent Protein Kinase 4 Suppresses Experimental Autoimmune Encephalomyelitis and Lupus-like Disease in Mice
Kotaro Otomo¹, Tomohiro Koga², Nobuya Yoshida³, Masayuki Mizui⁴, Christina Kriegel⁵, Tarek Fahmy⁶ and George C. Tsokos³, ¹Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Department of Rheumatology, Unit of Translational Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan, ³Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁴Department of Nephrology, Osaka University Graduate School of Medicine, Osaka, Japan, ⁵Department of Biomedical Engineering, Yale University, New Heaven, CT, ⁶Biomedical and Chemical Engineering, Yale University, New Heaven, CT
Background/Purpose: Treatment of autoimmune diseases is still based on the use of general immunosuppressive drugs which invariably cause severe side effects. This fact has compelled…
Abstract Number: 391 • 2015 ACR/ARHP Annual Meeting
Current Provider Practices and Perceived Barriers for Mental Health Care of Adolescents with SLE
Andrea Knight^1,2,3, Michelle Vickery², Eyal Muscal⁴, Alaina Davis⁵, Julia Harris⁶, Arzu Soybilgic⁷, Karen Onel⁸, Laura E. Schanberg⁹, Tamar Rubinstein¹⁰, Beth S. Gottlieb¹¹, Tracey Wright¹², Emily von Scheven¹³ and for the CARRA Investigators, ¹Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, ³Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Pediatric Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ⁵Pediatric Rheumatology, Vanderbilt University School of Medicine, Monroe Carell Junior Children's Hospital, Nashville, TN, ⁶Pediatric Rheumatology, Children’s Mercy Kansas City, Kansas City, MO, ⁷Pediatric Rheumatology, University of Illinois College of Medicine, Chicago, IL, ⁸Pediatric Rheumatology, Univ of Chicago, Chicago, IL, ⁹Dept of Pediatrics, Duke University Medical Center, Durham, NC, ¹⁰Division of Pediatric Rheumatology, Albert Einstein College of Medicine, Children's Hospital at Montefiore, Bronx, NY, ¹¹Pediatric Rheumatology, The Steven and Alexandra Cohen Children's Medical Center of New York, The Hofstra North Shore-LIJ School of Medicine, New Hyde Park, NY, ¹²Pediatrics/Rheumatology, UT Southwestern Medical Center, Dallas, TX, ¹³Dept of Pediatric Rheumatology, Univ of California San Francisco, San Francisco, CA
Background/Purpose: Depression and anxiety are common in adolescents with SLE. Barriers to mental health intervention in pediatric rheumatology care are unclear. We aimed to determine…
Abstract Number: 779 • 2015 ACR/ARHP Annual Meeting
Mapping Perceptions of Medication Decision Making Facilitators: The Importance of Patient Context
Haiyan Qu¹, Jinoos Yazdany², W. Winn Chatham³, Ricahrd Shewchuk⁴ and Jasvinder A. Singh¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of California, San Francisco, San Francisco, CA, ³Medicine/Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴University fo Alabama at Birmingham, Birmingham, AL
Background/Purpose: Our objective was to derive a cognitive map of how stakeholders perceive patient-identified facilitators to establish a theoretical framework for the purpose of developing…
Abstract Number: 1245 • 2015 ACR/ARHP Annual Meeting
Differential DNA Methylation Associated with Lupus Nephritis Shows Enrichment in Genes Involved in Regulation of TH2 Differentiation and Renal Development
Renuka Nayak¹, Sharon A. Chung², Joanne Nitiham³ and Lindsey A. Criswell³, ¹Department of Medicine, UCSF, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, University of California, San Francisco, San Francisco, CA, ²Russell/Englemen Rheumatology Research Center, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, University of California, San Francisco, San Francisco, CA, ³Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, University of California, San Francisco, San Francisco, CA
Background/Purpose: Genetic and epigenetic factors contribute to the progression of systemic lupus erythematosus (SLE). We have the ability to identify these factors and their influence…
Abstract Number: 1934 • 2015 ACR/ARHP Annual Meeting
Autophagy Pathway As a Target of Therapeutic P140 Peptide Used in Lupus
Maud Wilhelm¹, Fengjuan Wang², Nicolas Schall², Michael Faludi³, Jean Francois Kleinmann⁴, Emil P. Nashi⁵, Thierry Martin⁶, Jean Sibilia⁷, Jean-Louis Pasquali⁸, Daniel Wallace⁹ and Sylviane Muller¹⁰, ¹Immunopathologie & Chimie Thérapeutique, CNRS, Strasbourg, France, ²CNRS, Strasbourg, France, ³761 Graham, McGill University, Mont-Royal, QC, Canada, ⁴Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁵Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁶Cnrs UPR9021, IBMC, Strasbourg, France, ⁷Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁸Strasbourg University, Hospital, CNRS UPR 3572, Strasbourg, France, ⁹Cedars-Sinai/UCLA, Los Angeles, CA, ¹⁰CNRS Institut de Biologie Moléculaire et Cellulaire, Strasbourg, France
Background/Purpose: P140 is a 21-mer peptide (sequence 131-151, phosphorylated at position 140) that is derived from the spliceosomal protein U1-70K. In a multicenter, randomized, placebo-controlled…
Abstract Number: 3160 • 2015 ACR/ARHP Annual Meeting
Comparative Rates of Serious Infections and All-Cause Mortality Among Systemic Lupus Erythematosus Patients Receiving Mycophenolate Mofetil Versus Azathioprine
Candace H. Feldman¹, Francisco M. Marty², Wolfgang C. Winkelmayer³, Hongshu Guan⁴, Jessica M. Franklin⁵, Daniel H. Solomon¹, Seoyoung C. Kim⁶ and Karen H. Costenbader⁷, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Department of Medicine, Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, ³Medicine-Nephrology, Baylor College of Medicine, Houston, TX, ⁴Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁵Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁶Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁷Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at high risk of infections partly from use of immunosuppressives (IS). Clinical trials are powered to detect…
Abstract Number: 392 • 2015 ACR/ARHP Annual Meeting
From Childhood to Adulthood: Longitudinal Trajectory of Damage in Patients with Childhood-Onset Systemic Lupus Erythematosus (cSLE)
Lily Siok Hoon Lim^1,2,3,4, Eleanor Pullenayegum⁵, Lillian Lim⁶, Dafna Gladman⁷, Brian Feldman⁸ and Earl Silverman⁹, ¹Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, ON, Canada, ²Rheumatology, SickKids, Toronto, ON, Canada, ³Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ⁴Children's Hospital Research Institute of Manitoba, University of Manitoba, Winnipeg, MB, Canada, ⁵Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, ⁶Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada, ⁷Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸Division of Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁹Division of Rheumatology, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada
Background/Purpose: Outcomes of patients with cSLE over time and into adulthood are poorly understood. There has been no information about the longitudinal trajectory of organ…
Abstract Number: 788 • 2015 ACR/ARHP Annual Meeting
Identification of Molecular Biomarkers to Distinguish Systemic Lupus Erythematosus with Skin Involvement from Discoid Lupus Erythematosus and Subacute Cutaneous Erythematosus: Provisional Results from Cross-Sectional Studies
Matteo Cesaroni¹, Jarrat Jordan¹, Jessica Schreiter¹, Marc Chevrier¹, Grace Wang², Cesar Calderon³, Alexa Piantone², Ian Gourley⁴, Stanley Cohen⁵, Scott Fretzin⁶, Anna Wozniacka⁷, Victoria P. Werth⁸ and Jacqueline Benson¹, ¹Estrela Lupus Venture, Janssen Research and Development, LLC., Spring House, PA, ²Janssen Research and Development, Spring House, PA, ³37 Derwen Dr., Janssen Research and Development, Havertown, PA, ⁴1329 Anthony Wayne drive, Janssen Research and Development, Wayne, PA, ⁵Metroplex Clinical Research Center, LLC, Dallas, TX, ⁶Dawes Fretzin Clinical Research Group, LLCC, Indianapolis, IN, ⁷Medical University of Lodz, Lodz, Poland, ⁸Philadelphia VA Medical Center, Philadelphia, PA
Background/Purpose: Sub-classification of Lupus Erythematosus (LE) patients is largely based on defined clinical criteria while biological factors associating with or contributing to these clinical features…
Abstract Number: 1249 • 2015 ACR/ARHP Annual Meeting
Differential Expression of SLE Susceptibility Genes By Interferon-Alpha and the HLA-DRB1*03:01 Haplotype in Ex Vivo B Cells
Carolina Duarte¹, Lora Boteva², Timothy Vyse¹ and Michelle Fernando¹, ¹Division of Genetics and Molecular Medicine and Division of Immunology, Infection and Inflammatory Disease, King's College London, London, United Kingdom, ²MRC Human Genetics Unit, University of Edinburgh, Edinburgh, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex genetic autoimmune disease characterized by autoantibody production and up-regulation of type 1 interferons (IFNs). The strongest genetic association…
Abstract Number: 2074 • 2015 ACR/ARHP Annual Meeting
Dominant Chilblain Lupus Due to an Activating Mutation of Sting – Suppression of Constitutive Type I Interferon Activation By JAK Inhibition
Christoph Fiehn¹, Nadja König², Christine Wolf², Mathias Lesche³, Andreas Dahl³, Claudia Guenther⁴, Hanns-Martin Lorenz⁵ and Min Ae Lee-Kirsch², ¹ACURA Centre for Rheumatic Diseases, Baden-Baden, Germany, ²Department of Pediatrics, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, ³Department of Dermatology, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, ⁴Biotechnology Center, Technische Universität Dresden, Dresden, Germany, ⁵Department of Internal Medicine 5, Division of Rheumatology, University of Heidelberg, Heidelberg, Germany
Background/Purpose: Familial chilblain lupus is a monogenic form of cutaneous lupus erythematosus caused by mutations in the nucleases TREX1 or SAMHD1. The adapter molecule stimulator…
Abstract Number: 3161 • 2015 ACR/ARHP Annual Meeting
Rates of Hospitalization for Infection and Related Mortality By Race/Ethnicity and Sex Among Patients with End-Stage Renal Disease Due to Systemic Lupus Erythematosus
Candace H. Feldman¹, Francisco M. Marty², Wolfgang C. Winkelmayer³, Hongshu Guan⁴, Jessica M. Franklin⁵, Seoyoung C. Kim⁶, Daniel H. Solomon⁷ and Karen H. Costenbader^8,9, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Department of Medicine, Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, ³Medicine-Nephrology, Baylor College of Medicine, Houston, TX, ⁴Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁵Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁶Medicine, Division of Rheumatology, Division of Pharmacoepidemiology, Brigham & Women's Hospital, Boston, MA, ⁷Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ⁸Rheumatology, Brigham & Women's Hospital, Boston, MA, ⁹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Infections are a significant cause of morbidity and mortality in SLE patients. Recent studies show that lupus nephritis patients have more than two-fold higher…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].